Case report: Unique FLT4 variants associated with differential response to anlotinib in angiosarcoma

Angiosarcoma (AS) is a rare, clinically aggressive tumor with limited treatment options and a poor prognosis. Mutations involving the angiogenesis-related genesTP53, PTPRB, PLCG1, KDR as well as FLT4 amplification have been observed in AS. There is a potential therapeutic value of inhibition of the...

Descripción completa

Detalles Bibliográficos
Autores principales: Gu, Yuanyuan, Meng, Jing, Ju, Yongzhi, You, Xia, Sun, Tingting, Lu, Jun, Guan, Yin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9702819/
https://www.ncbi.nlm.nih.gov/pubmed/36452496
http://dx.doi.org/10.3389/fonc.2022.1027696
_version_ 1784839733228077056
author Gu, Yuanyuan
Meng, Jing
Ju, Yongzhi
You, Xia
Sun, Tingting
Lu, Jun
Guan, Yin
author_facet Gu, Yuanyuan
Meng, Jing
Ju, Yongzhi
You, Xia
Sun, Tingting
Lu, Jun
Guan, Yin
author_sort Gu, Yuanyuan
collection PubMed
description Angiosarcoma (AS) is a rare, clinically aggressive tumor with limited treatment options and a poor prognosis. Mutations involving the angiogenesis-related genesTP53, PTPRB, PLCG1, KDR as well as FLT4 amplification have been observed in AS. There is a potential therapeutic value of inhibition of the VEGF pathway against angiosarcoma. Our case first described a patient with two sites of cutaneous angiosarcomas (cASs) that responded differently to anlotinib. And genetic analysis revealed that those two sites had different FLT4 variants, suggesting that FLT4 amplification could be the cause of anlotinib non-response.
format Online
Article
Text
id pubmed-9702819
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-97028192022-11-29 Case report: Unique FLT4 variants associated with differential response to anlotinib in angiosarcoma Gu, Yuanyuan Meng, Jing Ju, Yongzhi You, Xia Sun, Tingting Lu, Jun Guan, Yin Front Oncol Oncology Angiosarcoma (AS) is a rare, clinically aggressive tumor with limited treatment options and a poor prognosis. Mutations involving the angiogenesis-related genesTP53, PTPRB, PLCG1, KDR as well as FLT4 amplification have been observed in AS. There is a potential therapeutic value of inhibition of the VEGF pathway against angiosarcoma. Our case first described a patient with two sites of cutaneous angiosarcomas (cASs) that responded differently to anlotinib. And genetic analysis revealed that those two sites had different FLT4 variants, suggesting that FLT4 amplification could be the cause of anlotinib non-response. Frontiers Media S.A. 2022-11-14 /pmc/articles/PMC9702819/ /pubmed/36452496 http://dx.doi.org/10.3389/fonc.2022.1027696 Text en Copyright © 2022 Gu, Meng, Ju, You, Sun, Lu and Guan https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Gu, Yuanyuan
Meng, Jing
Ju, Yongzhi
You, Xia
Sun, Tingting
Lu, Jun
Guan, Yin
Case report: Unique FLT4 variants associated with differential response to anlotinib in angiosarcoma
title Case report: Unique FLT4 variants associated with differential response to anlotinib in angiosarcoma
title_full Case report: Unique FLT4 variants associated with differential response to anlotinib in angiosarcoma
title_fullStr Case report: Unique FLT4 variants associated with differential response to anlotinib in angiosarcoma
title_full_unstemmed Case report: Unique FLT4 variants associated with differential response to anlotinib in angiosarcoma
title_short Case report: Unique FLT4 variants associated with differential response to anlotinib in angiosarcoma
title_sort case report: unique flt4 variants associated with differential response to anlotinib in angiosarcoma
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9702819/
https://www.ncbi.nlm.nih.gov/pubmed/36452496
http://dx.doi.org/10.3389/fonc.2022.1027696
work_keys_str_mv AT guyuanyuan casereportuniqueflt4variantsassociatedwithdifferentialresponsetoanlotinibinangiosarcoma
AT mengjing casereportuniqueflt4variantsassociatedwithdifferentialresponsetoanlotinibinangiosarcoma
AT juyongzhi casereportuniqueflt4variantsassociatedwithdifferentialresponsetoanlotinibinangiosarcoma
AT youxia casereportuniqueflt4variantsassociatedwithdifferentialresponsetoanlotinibinangiosarcoma
AT suntingting casereportuniqueflt4variantsassociatedwithdifferentialresponsetoanlotinibinangiosarcoma
AT lujun casereportuniqueflt4variantsassociatedwithdifferentialresponsetoanlotinibinangiosarcoma
AT guanyin casereportuniqueflt4variantsassociatedwithdifferentialresponsetoanlotinibinangiosarcoma

Ejemplares similares